A. Wozniak

发表

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

J. Crowley, K. Kelly, P. Bunn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of NRG1 Gene Fusions in Solid Tumors

Edward S. Kim, J. Nieva, A. Wozniak, 2019, Clinical Cancer Research.

Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

A. Wozniak, D. Gandara, A. Tsao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma.

A. Wozniak, Steven J. Cohen, N. Meropol, 2013, Practical Radiation Oncology.

Influence of diethylenetriamine (DETA) and sodium nitroprusside (NaNP) on sister chromatid exchange frequency and cell kinetics in cultured human lymphocytes.

A. Wozniak, J. Limon, M. Perkowska, 2001, Journal of applied genetics.

Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data

A. Wozniak, A. Schwartz, S. Gadgeel, 2016, Cancer.

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

A. Wozniak, P. LoRusso, J. Evelhoch, 2008, Investigational New Drugs.

Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.

A. Wozniak, L. Gaspar, G. Kalemkerian, 1999, Lung cancer.

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

A. Wozniak, T. Owonikoko, G. Dy, 2020, Clinical and translational science.

Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials

C. Gotay, R. Herbst, K. Kelly, 2007 .

A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

Jeffrey W. Clark, A. Wozniak, P. LoRusso, 2004, Investigational New Drugs.

Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks

A. Wozniak, P. LoRusso, M. Zalupski, 1995, Investigational New Drugs.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

C. Obasaju, P. Jänne, A. Wozniak, 2007, Lung cancer.

Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program

C. Obasaju, P. Jänne, A. Wozniak, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

T. Lynch, A. Wozniak, Priya Kumar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of Lung Cancer Associated with COPD Phenotype Based on Quantitative Image Analysis

Thomas Song, P. Kvale, A. Wozniak, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer

A. Wozniak, A. Schwartz, H. Mamdani, 2021, Clinical lung cancer.

SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma.

A. Wozniak, D. Gandara, A. Tsao, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC).

A. Wozniak, S. Gadgeel, G. Kalemkerian, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer

A. Wozniak, A. Turrisi, S. Gadgeel, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

R. Govindan, R. Herbst, K. Kelly, 2006, Lung cancer.

Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

A. Wozniak, S. Gadgeel, O. Kucuk, 2007, Clinical lung cancer.

Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.

T. Lynch, A. Wozniak, D. Spigel, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study

T. Lynch, A. Wozniak, M. Jahanzeb, 2015, Targeted Oncology.

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.

Edward S. Kim, G. Bepler, M. Oberley, 2021, Clinical lung cancer.

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy

Edward S. Kim, A. Wozniak, B. Levy, 2018, The Patient - Patient-Centered Outcomes Research.

Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

Shadan Ali, F. Sarkar, P. Philip, 2007, Cancer.

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.

J. Neal, H. Wakelee, L. Sequist, 2013 .

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

A. Wozniak, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiation pneumonitis (RP) in lung cancer patients treated with chemotherapy (CT) and thoracic radiation (TR): Retrospective analyses of patients treated at a comprehensive cancer center

A. Wozniak, S. Gadgeel, A. Soubani, 2007 .

Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program.

A. Wozniak, L. Gaspar, S. Ramalingam, 1999, Chest.

Exemptions to state laws regulating opioid prescribing for patients with cancer‐related pain: A summary

A. Wozniak, H. Bulls, Y. Schenker, 2021, Cancer.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC)

A. Wozniak, B. Halmos, S. Gadgeel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A. Drilon, M. Ahn, A. Wozniak, 2018, Cancer discovery.

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

A. Wozniak, P. LoRusso, R. Parchment, 2005, Clinical Cancer Research.

Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)

A. Wozniak, A. Shields, P. LoRusso, 2002, Investigational New Drugs.

A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design

B. Redman, A. Wozniak, P. LoRusso, 2003, Investigational New Drugs.

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.

Edward S. Kim, J. Nieva, A. Wozniak, 2018 .

A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.

A. Wozniak, E. Crawford, B. Blumenstein, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

A. Wozniak, L. Krug, J. Bauman, 2014, Lung cancer.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, J. Armitage, A. Wozniak, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC).

A. Wozniak, R. Parchment, S. Gadgeel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

A. Wozniak, E. Felip, J. Chaft, 2018 .

A Phase II Study of Mitomycin C, Etoposide, and Cisplatin in Advanced Non-Small Cell Lung Cancer

A. Wozniak, G. Kalemkerian, M. Valdivieso, 2000, Cancer investigation.

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

S. Gettinger, R. Heist, Gregory Riely, 2022, JTO clinical and research reports.

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors

A. Wozniak, J. Abrams, S. Gadgeel, 2019, Lung Cancer.

Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).

T. Lynch, A. Wozniak, S. Teng, 2010 .

Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay

A. Wozniak, P. LoRusso, F. Valeriote, 1992 .

Phase IClinicalTrial of BMS-247550 , ADerivative of Epothilone B , Using AcceleratedTitration 2 BDesign

A. Wozniak, P. LoRusso, R. Parchment, 2005 .

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, K. Kelly, A. Wozniak, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent vinorelbine in the treatment of non-small cell lung cancer.

A. Wozniak, 1999, Seminars in oncology.

Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.

J. Crowley, A. Wozniak, G. Weiss, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

A. Wozniak, S. Gadgeel, U. Vaishampayan, 2019, AntiCancer Research.

Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).

A. Wozniak, B. Halmos, S. Gadgeel, 2017 .

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Thomas J. Smith, Gary H Lyman, Thomas J Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

J. Crowley, M. Leblanc, I. Thompson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents.

A. Wozniak, W. Ross, B. Glisson, 1984, Cancer research.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

A. Wozniak, W. Ross, 1983, Cancer research.

Neurotoxicity of antineoplastic agents.

A. Wozniak, M. Hussain, M. Edelstein, 1993, Critical reviews in oncology/hematology.

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

A. Wozniak, S. Gadgeel, 2013, Clinical lung cancer.

Cyclophosphamide, methotrexate, and 5‐fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

A. Wozniak, E. Crawford, B. Blumenstein, 1993, Cancer.

Lung Cancer: Targets and Therapy Dovepress

A. Wozniak, M. Thakur, 2022 .

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials

F. Hirsch, K. Kelly, A. Wozniak, 2018, Clinical lung cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

A. Wozniak, Nadine H Abdallah, Dongping Shi, 2018, Lung Cancer.

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma

A. Wozniak, M. Thakur, 2017, Lung Cancer.

Antimicrotubule-Platinum Therapy in NSCLS by Histologic Subtypes 628-Introduction

F. Hirsch, A. Wozniak, D. Gandara, 2022 .

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma

H. Pass, A. Wozniak, M. Tsao, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic Oral Administration of CI-994: A Phase I Study

A. Wozniak, P. LoRusso, M. Meyer, 2004, Investigational New Drugs.

Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents

J. M. Shaw, A. Wozniak, P. LoRusso, 1995 .

Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.

A. Wozniak, P. LoRusso, W. Leopold, 1990, Cancer research.

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

A. Wozniak, G. Dy, S. Gadgeel, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.

A. Wozniak, 2012, Critical reviews in oncology/hematology.

Parameters for individualizing systemic therapy in non-small cell lung cancer.

G. Bepler, A. Wozniak, A. Schwartz, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

J. Crowley, F. Hirsch, A. Wozniak, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Refining the treatment of advanced nonsmall cell lung cancer.

A. Wozniak, S. Ogita, 2010, Lung Cancer.

Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009).

R. Govindan, A. Wozniak, T. Stinchcombe, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

L. Sequist, A. Wozniak, D. Harpole, 2009, Journal of Thoracic Oncology.

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Anand A. Dalal, N. Myall, H. Wakelee, 2019, Lung cancer.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021, Molecular Cancer Therapeutics.

Review: Adjuvant therapy for resected non-small cell lung cancer

A. Wozniak, S. Gadgeel, 2009, Therapeutic advances in medical oncology.

Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts)

A. Wozniak, A. Turrisi, S. Gadgeel, 2008 .

A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).

C. Gotay, C. Moinpour, A. Wozniak, 2012, The oncologist.

"I Refused to Get Addicted to Opioids": Exploring Attitudes about Opioid Use Disorder in Patients with Advanced Cancer Pain and their Support People.

A. Wozniak, H. Bulls, Y. Schenker, 2023, The journal of pain.

Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer

A. Wozniak, S. Gadgeel, G. Kalemkerian, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor Efficacy of PD 115934 ( NSC 366140 ) against Solid Tumors of Mice 1

A. Wozniak, P. LoRusso, W. Leopold, 2006 .

Activity of flavone acetic acid (NSC-347512) against solid tumors of mice

A. Wozniak, F. Valeriote, J. Plowman, 2004, Investigational New Drugs.

Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.

F. Hirsch, K. Kelly, A. Wozniak, 2013, Clinical lung cancer.

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.

K. Kelly, A. Wozniak, D. Gandara, 2015, Clinical lung cancer.

Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?

A. Wozniak, S. Gadgeel, 2007, Oncology.

A Phase II Study of Weekly Alternating Chemotherapy in Extensive-Stage Small Cell Lung Cancer

A. Wozniak, G. Kalemkerian, M. Valdivieso, 2001, Cancer investigation.

Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509

K. Kelly, A. Wozniak, D. Gandara, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical presentation of non-small cell carcinoma of the lung

A. Wozniak, S. Gadgeel, 2012 .

Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.

A. Wozniak, G. Warsi, A. Gajra, 2010, Lung cancer.

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer

R. Dunn, A. Wozniak, R. Parchment, 2009, Investigational New Drugs.

Comparing Treatment Strategies for Stage I Small‐cell lung Cancer

A. Wozniak, J. Beebe-Dimmer, S. Gadgeel, 2018, Clinical lung cancer.

Title: Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021 .

A framework for opioid stigma in cancer pain.

A. Wozniak, E. Chu, H. Bulls, 2021, Pain.

5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer

S. Martino, B. Redman, A. Wozniak, 1991, Cancer.

Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy

A. Wozniak, S. Gadgeel, G. Kalemkerian, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

A. Wozniak, E. Heath, S. Gadgeel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Manifestations of Opioid Stigma in Patients With Advanced Cancer: Perspectives From Patients and Their Support Providers

A. Wozniak, H. Bulls, Y. Schenker, 2022, JCO oncology practice.

Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).

A. Wozniak, M. Edelman, S. Gadgeel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.

A. Wozniak, I. Massova, W. Leopold, 1993, Journal of medicinal chemistry.

SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

S. Ou, A. Wozniak, D. Gandara, 2012 .

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data

A. Wozniak, J. Ruterbusch, J. Beebe-Dimmer, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

Shadan Ali, F. Sarkar, P. Philip, 2009, Cancer.

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

A. Wozniak, S. Gadgeel, G. Kalemkerian, 2010, Clinical lung cancer.

Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non–Small‐Cell Lung Cancer

A. Wozniak, M. Dominello, S. Gadgeel, 2017, Clinical lung cancer.

Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP).

R. Govindan, A. Wozniak, T. Hensing, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Dose‐dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non–Small‐cell Lung Cancer

A. Wozniak, S. Gadgeel, G. Kalemkerian, 2017, Clinical lung cancer.

Effectiveness of bevacizumab exposure beyond disease progression in patients with non–small‐cell lung cancer: analyses of the ARIES observational cohort study

A. Wozniak, D. Spigel, J. Brahmer, 2016, Pharmacoepidemiology and drug safety.